NASDAQ:CPIXCumberland Pharmaceuticals Stock Price, Forecast & News

$3.47

+0.13 (+3.89 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$3.25

Now: $3.47▼

$3.47

50-Day Range

$3.25

MA: $3.75▼

$4.00

52-Week Range

$3.10

Now: $3.47▼

$6.51

Volume79,399 shs

Average Volume78,790 shs

Market Capitalization$52.67 million

P/E RatioN/A

Dividend YieldN/A

Beta0.39

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections. The company's Phase II product candidates includes Hepatoren injection for the treatment of critically ill patients suffering from liver and kidney failure; Boxaban oral capsules for the treatment of asthma patients; Vasculan oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as severe disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Cumberland Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.75, Cumberland Pharmaceuticals has a potential upside of 181.0% from its current price of $3.47.
Amount of Analyst Coverage
Cumberland Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.2 Community Rank

Outperform Votes
Cumberland Pharmaceuticals has received 182 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cumberland Pharmaceuticals has received 237 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cumberland Pharmaceuticals has received 56.56% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cumberland Pharmaceuticals and other stocks. Vote “Outperform” if you believe CPIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CPIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cumberland Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Cumberland Pharmaceuticals does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cumberland Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
39.72% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 30.80% of the stock of Cumberland Pharmaceuticals is held by institutions.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Cumberland Pharmaceuticals are expected to grow by 400.00% in the coming year, from $0.03 to $0.15 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cumberland Pharmaceuticals is -11.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cumberland Pharmaceuticals is -11.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cumberland Pharmaceuticals has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.72 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNASDAQ:CPIX

Previous Symbol

CUSIP23077010

CIK1087294

Webwww.cumberlandpharma.com

Phone615-255-0068

Debt

Debt-to-Equity Ratio0.37

Current Ratio2.31

Quick Ratio1.89

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio115.67

P/E GrowthN/A

Sales & Book Value

Annual Sales$47.53 million

Price / Sales1.11

Cash Flow$0.54 per share

Price / Cash Flow6.43

Book Value$3.36 per share

Price / Book1.03

Profitability

EPS (Most Recent Fiscal Year)$0.23

Net Income$-3,540,000.00

Net Margins-10.28%

Return on Equity3.78%

Return on Assets1.89%

Miscellaneous

Employees80

Outstanding Shares15,180,000

Market Cap$52.67 million

Next Earnings Date8/12/2020 (Estimated)

OptionableOptionable

Receive CPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.

Cumberland Pharmaceuticals (NASDAQ:CPIX) Frequently Asked Questions

How has Cumberland Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Cumberland Pharmaceuticals' stock was trading at $4.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CPIX stock has decreased by 16.2% and is now trading at $3.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cumberland Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cumberland Pharmaceuticals.

When is Cumberland Pharmaceuticals' next earnings date?

Cumberland Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Cumberland Pharmaceuticals.

How were Cumberland Pharmaceuticals' earnings last quarter?

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) issued its earnings results on Wednesday, May, 20th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.01. The specialty pharmaceutical company had revenue of $8.33 million for the quarter, compared to the consensus estimate of $9.46 million. Cumberland Pharmaceuticals had a positive return on equity of 3.78% and a negative net margin of 10.28%. View Cumberland Pharmaceuticals' earnings history.

What price target have analysts set for CPIX?

1 brokers have issued 12 month price targets for Cumberland Pharmaceuticals' shares. Their forecasts range from $9.75 to $9.75. On average, they expect Cumberland Pharmaceuticals' share price to reach $9.75 in the next twelve months. This suggests a possible upside of 181.0% from the stock's current price. View analysts' price targets for Cumberland Pharmaceuticals.

Has Cumberland Pharmaceuticals been receiving favorable news coverage?

News headlines about CPIX stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cumberland Pharmaceuticals earned a daily sentiment score of -4.4 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. View the latest news aboutCumberland Pharmaceuticals.

Who are some of Cumberland Pharmaceuticals' key competitors?

Some companies that are related to Cumberland Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Zogenix (ZGNX). View all competitors.

What other stocks do shareholders of Cumberland Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include The Ensign Group (ENSG), MYR Group (MYRG), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Avid Technology (AVID), Alibaba Group (BABA), Bank of America (BAC), Protalix Biotherapeutics (PLX), Dr.Reddy's Laboratories (RDY) and Ring Energy (REI).

Who are Cumberland Pharmaceuticals' key executives?

Cumberland Pharmaceuticals' management team includes the following people:

Mr. A. J. Kazimi, Founder, Chairman, Pres & CEO (Age 61)
Mr. Michael P. Bonner, CFO and Sr. Director of Fin. & Accounting (Age 42)
Mr. Leo B. Pavliv, Exec. VP of Operations & Chief Devel. Officer (Age 58)
Mr. James Lowrance Herman, Sr. VP of National Accounts & Chief Compliance Officer (Age 64)
Mr. Martin E. Cearnal, Exec. VP of Marketing & Sales, Chief Commercial Officer and Director (Age 74)

What is Cumberland Pharmaceuticals' stock symbol?

Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."

Who are Cumberland Pharmaceuticals' major shareholders?

Cumberland Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (5.98%), BlackRock Inc. (2.16%), Acadian Asset Management LLC (0.61%) and Morgan Stanley (0.08%). Company insiders that own Cumberland Pharmaceuticals stock include A J Kazimi, Caroline Young, Gordon R Bernard, Joey A Jacobs, Joseph C Galante, Kenneth Krogulski and Michael Bonner. View institutional ownership trends for Cumberland Pharmaceuticals.

Which major investors are selling Cumberland Pharmaceuticals stock?

CPIX stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, BlackRock Inc., and Morgan Stanley. View insider buying and selling activity for Cumberland Pharmaceuticals.

Which major investors are buying Cumberland Pharmaceuticals stock?

CPIX stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include A J Kazimi, Caroline Young, Joey A Jacobs, Joseph C Galante, Kenneth Krogulski, and Michael Bonner. View insider buying and selling activity for Cumberland Pharmaceuticals.

How do I buy shares of Cumberland Pharmaceuticals?

Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cumberland Pharmaceuticals' stock price today?

One share of CPIX stock can currently be purchased for approximately $3.47.

How big of a company is Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals has a market capitalization of $52.67 million and generates $47.53 million in revenue each year. The specialty pharmaceutical company earns $-3,540,000.00 in net income (profit) each year or $0.23 on an earnings per share basis. Cumberland Pharmaceuticals employs 80 workers across the globe.

What is Cumberland Pharmaceuticals' official website?

The official website for Cumberland Pharmaceuticals is www.cumberlandpharma.com.

How can I contact Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at 615-255-0068 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff